Exyte Strengthens European Biotech and Pharma Presence with TTP Acquisition
Deal News | Feb 06, 2025 | goetzpartners
Exyte GmbH, a leader in high-tech facility solutions, has acquired TTP Group, renowned for its consulting and engineering in the pharmaceutical and chemical sectors across Europe, in a deal completed in October 2024. TTP, with its operational brands Pharmaplan and Triplan, serves a wide spectrum of blue-chip clients by offering services ranging from engineering to validation. The acquisition aligns with Exyte’s strategy to bolster its Biopharma and Life Sciences operations in Europe. With the support of Fortlane Partners, acting as M&A advisor, Exyte aims to enhance its capabilities in the rapidly growing European biotechnology and pharmaceutical industry. This strategic acquisition demonstrates Fortlane's proficiency in advising high-tech engineering clients. Exyte, known for its work in semiconductors, battery cells, and data centers, reported sales of $7.1 billion in 2023 with nearly 9,900 employees globally.
Sectors
- Pharmaceutical and Biotechnology
- Engineering and Construction
Geography
- Europe – The transaction signifies Exyte's expansion within the European biotechnology and pharmaceutical markets, with TTP operating in Germany, Switzerland, Austria, France, and Belgium.
Industry
- Pharmaceutical and Biotechnology – The acquisition of TTP by Exyte emphasizes growth and partnerships within the pharmaceutical and biotechnology sectors, aligning with TTP's consultancy and engineering services for these industries.
- Engineering and Construction – Exyte’s worldwide operations focus on designing and delivering ultra-clean and sustainable facilities complementing TTP’s services in pharmaceutical and chemical engineering, making this sector highly relevant.
Financials
- 7.1 billion – Exyte’s sales revenue for 2023.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Exyte GmbH | Acquiring Company | Company | Exyte is a global leader in the design, engineering, and implementation of ultra-clean and sustainable facilities for high-tech industries. |
| TTP Group | Target Company | Company | TTP specializes in consulting and engineering services within the pharmaceutical and chemical industries, operating under the brands Pharmaplan and Triplan. |
| Fortlane Partners | M&A Advisor | Company | Acted as sole and exclusive buy-side advisor for Exyte in the acquisition of TTP Group. |
| Robus Capital | Selling Company (Vendor) | Company | Funds advised by Robus Capital were among the sellers of TTP Group. |
| Christian Muthler | Managing Director | Person | Christian Muthler is part of the transaction team at Fortlane Partners. |
| Maximilian Bergold | Director | Person | Maximilian Bergold is part of the transaction team at Fortlane Partners. |
| Markus Rosen | Director | Person | Markus Rosen is part of the transaction team at Fortlane Partners. |
| Matthias Friedl | Associate | Person | Matthias Friedl, CFA, is part of the transaction team at Fortlane Partners. |
| Christoph Pfeifer | Analyst | Person | Christoph Pfeifer is part of the transaction team at Fortlane Partners. |